Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05NDR
|
|||
| Former ID |
DCL000640
|
|||
| Drug Name |
Sifalimumab
|
|||
| Synonyms |
Cci 779; CHEBI:79699; Torisel (TN); 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin; Temsirolimus (JAN/USAN/INN); 162635-04-3; DB06287; C15182; D06068; J-524319; (1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,18R,19R,21R,23S,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0; {4,9}]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Renal cell carcinoma [ICD-11: 2C90; ICD-10: C64; ICD-9: 189] | Approved | [1], [2] | |
| Systemic lupus erythematosus [ICD-11: 4A40.0] | Phase 2 | [1], [3] | ||
| Company |
AstraZeneca; MedImmune
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interferon alpha/beta receptor 2 (IFNAR2) | Target Info | . | [3], [4] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| PI3K-Akt signaling pathway | ||||
| Osteoclast differentiation | ||||
| Toll-like receptor signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Natural killer cell mediated cytotoxicity | ||||
| Hepatitis C | ||||
| Hepatitis B | ||||
| Measles | ||||
| Influenza A | ||||
| Herpes simplex infection | ||||
| Reactome | Interferon alpha/beta signaling | |||
| Regulation of IFNA signaling | ||||
| WikiPathways | Toll-like receptor signaling pathway | |||
| Interferon type I signaling pathways | ||||
| Interferon alpha/beta signaling | ||||
| Regulation of toll-like receptor signaling pathway | ||||
| Osteoclast Signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8257). | |||
| REF 2 | 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9. | |||
| REF 3 | Clinical pipeline report, company report or official report of MedImmune (2011). | |||
| REF 4 | Clinical pipeline report, company report or official report of AstraZeneca (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.